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Abstract
Aims: Although there is still no clear definition of ‘‘adipose tissue dysfunction’’ or ATD, the identification of a clinical marker
of altered fat distribution and function may provide the needed tools for early identification of a condition of
cardiometabolic risk. Our aim was to evaluate the correlations among various anthropometric indices [BMI, Waist
Circumference (WC), Hip Circumference (HC), Waist/Hip ratio (WHR), Body Adiposity Index (BAI) and Visceral adiposity Index
(VAI)] and several adipocytokines [Visfatin, Resistin, Leptin, Soluble leptin receptors (sOB-R), Adiponectin, Ghrelin, Adipsin,
PAI-1, vascular endothelial growth factor (VEGF), Hepatocyte growth factor (HGF) TNF-a, hs-CRP, IL-6, IL-18] in patients with
type 2 diabetes (DM2).
Materials and Methods: Ninety-one DM2 patients (age: 65.2566.38 years; 42 men and 49 women) in stable treatment for
the last six months with metformin in monotherapy (1.5–2 g/day) were cross-sectionally studied. Clinical, anthropometric,
and metabolic parameters were evaluated. Serum adipocytokine levels were assayed with Luminex based kits.
Results: At the Pearson’s correlation, among all the indices investigated, VAI showed a significant correlation with almost all
adipocytokines analyzed [Visfatin, Resistin and hsCRP (all p,0.001); Adiponectin, sOb-R, IL-6, IL-18, HGF (all p,0.010);
Ghrelin and VEGF (both p,0.05)]. Through a two-step cluster analysis, 55 patients were identified with the most altered
adipocytokine profile (patients with ATD). At a ROC analysis, VAI showed the highest C-statistic [0.767 (95% CI 0.66–0.84)] of
all the indices.
Conclusions: Our study suggests that the VAI, among the most common indexes of adiposity assessment, shows the best
correlation with the best known adipocytokines and cardiometabolic risk serum markers. Although to date we are still far
from clearly identifying an ATD, the VAI would be an easy tool for clearly mirroring a condition of cardiometabolic risk, in the
absence of an overt metabolic syndrome.
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Introduction
Metabolically complicated obesity and its associated insulin
resistance are increasingly prevalent and contribute to increasing
the prevalence of type 2 diabetes and cardiovascular disease [1–3],
two major causes of morbidity and mortality in our population.
Excessive triglyceride storage in adipocytes, due to weight
increase, is known to induce changes in adipose tissue (AT), such
as adipocyte insulin resistance (resulting in higher lipolytic
activity), decreased adiponectin production, increased TNF-a,
IL-6 production and increase in several other adipocytokines.
These changes are characteristic of ‘‘adipose tissue dysfunction’’
(ATD) or ‘‘adiposopathy’’ [4] which is often associated with
diabetes mellitus, hypertension and diabetic dyslipidemia [low
high-density lipoprotein cholesterol (HDL-C) and raised triglycer-
ides]. However, this condition is not necessarily associated with
obesity; it can occur with a mild increase in body weight, even
within the nonobese range [5,6]; conversely, the threshold may not
be reached even in the presence of obesity [7]. Therefore, the
existence of simple tools for clinical evaluation of this condition
would allow better identification of people at risk for systemic
metabolic complications and lay the foundation for developing
more effective strategies to prevent such complications as ectopic
fat deposition and systemic insulin resistance.
In 2010 we modelled the Visceral adiposity index (VAI), a
gender-specific mathematical index based on simple anthropo-
metric [BMI and waist circumference (WC)] and metabolic
[Triglycerides (TG) and HDL Cholesterol (HDL)] parameters,
as a presumed surrogate marker of adipose tissue function and
distribution, independently linked to insulin sensitivity and
cardiometabolic risk in the general population [8]. In the last
three years, the VAI has been reported on in 30 publications, in
which its capacity to express cardiometabolic risk and possible
ATD was identified.
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The most important results were obtained in populations at
metabolic risk not always having an overt metabolic syndrome,
such as the general population [9–12], post-menopausal women
[13] and women with Polycystic Ovary Syndrome [14]. Recently,
in a population of young women with PCOS, the VAI proved to
be able to replace visceral Computed Tomography scanning as a
marker for visceral adiposity and to predict insulin resistance [15].
These findings have led to the proposal of a precise VAI cut-off to
differentiate the ‘‘metabolically healthy polycystic ovary syn-
drome’’ from the ‘‘metabolically unhealthy polycystic ovary
syndrome’’ [16].
Also, in patients with non-alcoholic fatty liver disease, the VAI is
linked to significant fibrosis [17,18], while it is not more powerful
than WC in discriminating steatosis from steatohepatitis [19]; in
patients with HCV, the VAI showed an independent association
with both steatosis and necroinflammatory activity and has a
Table 1. Clinical characteristics and pattern of adipocytokine secretion in the patients with type 2 diabetes.
Women Men Total
No 49 No 42 No 91
Mean 6 SD Mean 6 SD Mean 6 SD
Age (years) 62.3766.67 62.1266.10 62.2566.38
Duration of disease (years) 9.5366.50 9.9565.40 9.7365.99
BMI (Kg/m2) 30.3564.94* 28.3664.09 29.4364.65
Waist Circumference (cm) 103.02612.43 101.93610.10 102.52611.36
Hip Circumference (cm) 110.30611.66* 103.6667.40 107.24610.42
Waist/Hip ratio 0.9360.10* 0.9860.04 0.9560.08
Body Adiposity Index 37.0966.27** 30.3164.17 33.9666.35
Visceral Adiposity Index 2.6461.56* 1.8760.94 2.2961.36
HbA1c (%) 6.9460.68 6.8860.57 6.9260.63
HbA1c (mmol/mol) 5267.40 5266.20 5266.90
HOMA-IR 2.9863.02 3.2663.44 3.1163.21
Fasting Insulin (pmol/l) 61.75663.33 68.94672.31 65.07667.33
Fasting C-peptide (nmol/l) 0.1460.16 0.1660.15 0.1560.15
Urinary Albumin-to-Creatinine Ratio (UACR) (mg/g) 16.13647.53 17.05626.31 16.55638.99
Fasting lipids
Total Cholesterol (mmol/l) 4.6760.78 4.5360.97 4.6060.87
HDL Cholesterol (mmol/l) 1.3160.31 1.2060.32 1.2560.32
LDL Cholesterol (mmol/l) 2.7560.82 2.7960.91 2.7760.86
Triglycerides (mmol/l) 1.4560.61 1.3660.51 1.4160.57
NEFA (mmol/l) 0.5460.27* 0.3960.24 0.4760.26
Fasting adipocytokines
Leptin (ng/dl)1 13.74612.02** 3.5964.79 9.06610.65
Soluble leptin receptor (sOb-R) (ng/ml) 19.8966.18* 23.1066.40 21.3766.46
Leptin/sOb-R ratio1 0.8961.09** 0.2060.34 0.5760.90
Adiponectin (mg/ml) 1 10.95612.10 13.24614.37 12.01613.17
Visfatin (ng/ml) 0.6460.56 0.6160.50 0.6260.53
Resistin (ng/ml) 1 3.7864.36 4.4265.28 4.0764.79
Ghrelin (pmol/l) 31.4969.96 30.8367.66 31.1968.93
Adipsin (mg/ml) 0.6360.35 0.7060.30 0.6760.33
PAI-1 (ng/ml) 83.51678.96 83.78686.79 83.63682.20
TNF-a (pg/ml) 1 1.4361.62 1.4961.64 1.4661.62
IL-6 (pg/ml) 2.2462.42 2.2162.18 2.2262.30
IL-18 (pg/ml) 1 41.75627.32 39.13624.47 40.54625.93
VEGF (pg/ml) 106.26690.91 117.816104.69 111.59697.13
HGF (pg/ml) 351.826185.87 385.226209.67 367.236196.80
hs-CRP (mg/l) 1 0.5060.67 0.9764.44 0.7263.04
Women vs. Men:
* p,0.05,
**p,0.001; Student’s t Test after testing for equality of variance (Levene test) and after natural log transformation of several variables (1).
doi:10.1371/journal.pone.0091969.t001
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direct correlation with viral load [20]; in patients with acromegaly,
the VAI appears to be associated with disease activity, adiponectin
levels and insulin sensitivity and secretion, and is influenced
independently of GH levels [21].
However, in all these studies the ability of the VAI to express the
adipose tissue function was only a hypothesis, few studies existing
that have evaluated the correlation between it and levels of
adipocytokine [9,17,21].
The aim of this study is to evaluate the relationship between the
VAI and other common anthropometric measures of fat
distribution [BMI, WC, Hip Circumference (HC), Waist-hip ratio
(WHR), Body Adiposity Index (BAI)], on the one hand, and a
complete panel of adipocytokines [Resistin, Leptin, Soluble Leptin
Receptor (sOB-R), Leptin/sOB-R ratio, Adiponectin, Visfatin,
Ghrelin, Adipsin, PAI, Vascular-endothelial growth factor
(VEGF), TNF-a, hs-CRP, IL-6, IL-18, Hepatocyte growth factor
(HGF)], on the other, in patients with type 2 diabetes mellitus
(DM2).
Materials and Methods
Subjects
This study was approved by the Institutional Review Board at
the Faculty of Medicine of the University of Palermo. At the time
of observation all patients regularly signed an informed consent for
the scientific use of their data.
Ninety-one consecutive Caucasian patients with DM2 (mean
age 62.2566.38 years; range: 51–75), followed up in our dedicated
Table 2. Bivariate correlations between anthropometric measures and adipocytokine, lipid and glycemic parameters.
BMI WC HC WHR BAI VAI
ADIPOCYTOKINES
Ln Leptin 0.454*** 0.400*** 0.535*** 20.045 0.542*** 0.239*
sOb-R 20.436*** 20.412*** 20.300** 20.204 20.239* 20.278**
Ln Leptin/sOb-R ratio 0.491*** 0.435*** 0.526*** 0.008 0.521*** 0.270**
Ln Adiponectin 20.002 0.053 0.109 20.060 0.006 20.330**
Visfatin 0.116 0.115 0.093 0.036 0.087 0.375***
Ln Resistin 0.045 0.217* 0.103 0.156 20.028 0.379***
Ghrelin 20.228* 20.296** 20.108 20.263* 20.045 20.225*
Adipsin 20.008 0.115 0.078 0.055 0.004 0.025
PAI-1 0.013 0.107 0.008 0.153 20.004 0.086
Ln TNF-a 20.007 0.003 20.206 0.213* 20.180 0.170
IL-6 0.145 0.187 0.015 0.233* 0.083 0.300**
Ln IL-18 20.052 20.095 0.001 20.134 0.076 0.340**
VEGF 0.072 0.097 20.097 0.250* 20.197 0.211*
HGF 0.076 0.200 0.065 0.177 0.039 0.298**
Ln hs-CRP 0.155 0.233* 0.171 0.120 0.158 0.419***
LIPID PATTERN
Total Cholesterol 20.082 20.165 20.078 20.122 0.046 0.316**
HDL Cholesterol 20.087 20.065 0.113 20.194 0.145 –
Triglycerides 0.107 0.051 0.069 0.003 0.115 –
LDL Cholesterol 20.075 20.152 20.144 20.041 20.062 0.286**
NEFA 0.060 20.011 0.042 20.051 0.205 0.327**
GLYCEMIC PATTERN
HOMA IR 0.373*** 0.465*** 0.421*** 0.122 0.236* 0.324**
Fasting C-Peptide 0.228* 0.250* 0.325** 20.028 0.129 0.228*
Fasting Insulin 0.336** 0.449*** 0.426*** 0.097 0.220* 0.329**
Fasting glucose 0.184 0.262* 0.098 0.216* 0.075 0.031
2 h after breakfast glucose 20.067 0.026 20.105 0.162 20.076 0.166
2 h after lunch glucose 0.024 0.089 0.006 0.089 20.037 0.069
2 h after dinner glucose 0.070 0.157 0.094 0.078 0.085 0.128
HbA1c 0.127 0.268* 0.132 0.202 0.125 0.250*
BMI: Body Mass Index; WC: Waist Circumference; HC: Hip Circumference; WHR: Waist/Hip ratio; BAI: Body Adiposity Index; VAI: Visceral adiposity Index; sOb-R: Soluble
leptin receptor; PAI-1: Plasminogen activator inhibitor-1; TNF-a: Tumor necrosis factor alpha; IL-6: Interleukin 6; IL-18: Interleukin 18; VEGF: Vascular endothelial growth
factor; HGF: Hepatocyte growth factor; Hs-CRP: high-sensitivity C reactive protein.
Bivariate Pearson correlation: the value indicates r coefficient.
*p,0.050;
**p,0.010;
***p,0.001.
doi:10.1371/journal.pone.0091969.t002
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Outpatients Clinic (from January 1st 2011 to December 31st
2012), were cross-sectionally studied. Inclusion criteria were a 2-
year or longer history of DM2 at study entry, in stable treatment
for the last six months with metformin (1.5–2 g/day). Only
patients were included who had HbA1c #8 (64 mmol/mol), in
order to avoid the effects of severe glucotoxicity on the
adipocytokines. The following were excluded: patients with type
1 diabetes, patients with previous treatment with other anti-
diabetic drugs in the past six months, patients with morbid obesity,
pendulous abdomen, severe hypertriglyceridemia and/or or use of
Figure 1. Differences in serum levels of adipocytokines between Cluster 1 (DM2 patients without ‘‘adipose tissue dysfunction’’) and
Cluster 2 (DM2 patients with ‘‘hypothetical adipose tissue dysfunction’’).
doi:10.1371/journal.pone.0091969.g001
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fibrates [22]. Also excluded were patients with macro- or
microvascular complications (except 7 patients with simple
preproliferative retinopathy). Patients were not excluded that
had essential hypertension (58 patients). In the patients included a
complete medical history, a complete physical examination, body
weight, height, waist and hip circumference were recorded. Waist
circumference (WC) was measured midway between the inferior
margin of the last rib and the crest of the ilium in a horizontal
plane by the measurer sitting by the subject and fitting the tape
snugly, but not compressing soft tissues. Hip circumference (HP)
was measured around the pelvis at the point of maximal
protrusion of the buttocks. Fasting blood samples and a morning
spot urine sample were collected for biochemical analyses. All
participants were instructed to perform home glucose monitoring
(one full day glucose profile per week: fasting, 2 h after breakfast,
2 h after lunch and 2 h after dinner).
Anthropometric Indices
BMI was calculated as body weight (in kilograms) divided by the
square of height (in meters). WHR and was calculated by dividing
the waist circumference by the hip circumference. Body adiposity
Index (BAI) was calculated using the following formula [23]:
BAI~ HCð Þ7 heightð Þð Þ|1:5ð Þ{1:8
HC is expressed in centimeters and height in meters.
The VAI was calculated as described [8,22] using the following
sex-specific equation, where TG is triglyceride levels expressed in
mmol/l and HDL is HDL-cholesterol levels expressed in mmol/l:
Females : VAI~
WC
36:58z 1:89|BMIð Þ
 
|
TG
0:81
 
|
1:52
HDL
 
Males : VAI~
WC
39:68z 1:88|BMIð Þ
 
|
TG
1:03
 
|
1:31
HDL
 
Assay
The BioPlex Pro Human Diabetes 10-plex assay (BioRad,
Milan, Italy) was used to quantitate the following diabetes-related
analytes: C-peptide (nmol/l), Ghrelin (pg/ml), Leptin (ng/ml),
PAI-1 (ng/ml), Resistin (ng/ml) and visfatin (pg/ml). The BioPlex
Pro Human Diabetes Adipsin and Adiponectin duplex assay
(BioRad, Milan, Italy) was used for Adipsin (ng/ml) and
Adiponectin (mg/ml) assays. A customized BioPlex 3-plex assay
(BioRad, Milan, Italy) was used for the quantitation of serum IL-6
(pg/ml), TNF-a (pg/ml) and VEGF pg/ml. A customized BioPlex
duplex assay (BioRad, Milan, Italy) was used for the quantitation
of IL-18 (pg/ml) and HGF (pg/ml). All these assays were run on a
BioPlex 200 workstation (BioRad, Milan, Italy). Human sOb-R
(ng/ml) was assayed using an ELISA sandwich enzyme immuno-
assay (Human leptin receptor ELISA, BioVendor, Heidelberg,
Germany). Serum non-esterified fatty acids (NEFA) (mmol/l) were
assayed after overnight fasting using an enzymatic colorimetric
method (Randox NEFA assay FA115, Randox Laboratories,
County Antrim, UK). CRP (mg/l) was determined by a high
Table 3. Differences in anthropometric and glycometabolic characteristics between cluster 1 and cluster 2.
Cluster 1 Cluster 2
No 36 No 55
Mean 6 SD Mean 6 SD p
Age (years) 62.8365.48 61.8766.92 0.486
Duration of disease (years) 10.5666.45 9.1865.66 0.301
BMI (Kg/m2) 28.3364.08 30.1564.90 0.060
Waist Circumference (cm) 100.36612.07 103.93610.76 0.155
Hip Circumference (cm) 107.61611.19 10769.98 0.791
Waist/Hip ratio 0.9360.08 0.9760.08 0.036
Body Adiposity Index 33.2766.53 34.4166.26 0.412
Visceral Adiposity Index 1.5760.75 2.7661.47 ,0.001
HbA1c (%) 6.8360.59 6.9760.66 0.285
HbA1c (mmol/mol) 5166.4 5367.2 0.285
HOMA-IR 2.4662.59 3.5363.51 0.099
Fasting Insulin (pmol/l) 54.40660.47 72.06671.14 0.208
Fasting C-peptide (nmol/l) 0.1360.10 0.1660.18 0.229
Fasting glucose (mmol/l) 7.3661.27 7.6961.69 0.292
2 h after breakfast glucose (mmol/l) 6.7961.07 6.8661.74 0.806
2 h after lunch glucose (mmol/l) 7.5161.41 7.5961.96 0.821
2 h after dinner glucose (mmol/l) 7.3161.74 7.9861.98 0.093
Urinary Albumin-to-Creatinine Ratio (UACR) (mg/g) 19.83655.35 14.41623.15 0.581
Student’s t Test after testing for equality of variance (Levene test).
doi:10.1371/journal.pone.0091969.t003
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sensitivity immunonephelometric method (CardioPhase hs CRP,
SIEMENS) on the BNTN II System (SIEMENS). Blood glucose
levels (mg/dl) were measured using an electrochemical system
(Glucocard, Menarini Diagnostics, Italy). Total cholesterol, HDL
cholesterol, triglycerides and urinary albumin and creatinine were
measured in our laboratory using standard assays. HbA1c was
determined by High Pressure Liquid Chromatography (HPLC)
with ion-exchange resin (HA8121, Hi-AutoA1c, Menarini, Italy).
LDL cholesterol levels were calculated with Friedewald’s formula.
The conversion factors for the International System (SI) were the
following: glucose (mg/dl vs. mmol/l; X 0.0555), insulin (mUI/l
vs. pmol/l; X 6.945), total cholesterol (mg/dl vs. mmol/l; X
0.0259), visfatin (pg/ml vs. ng/ml; :1000), Ghrelin (pg/ml vs
pmol/l; X 0.296), Adipsin (ng/ml vs. mg/ml; :1000).
Statistical Methods
The Statistical Packages for Social Sciences SPSS version 17
and MedCalc version 11.3 were used for data analysis. Baseline
characteristics were presented as mean6 Standard Deviation (SD)
for continuous variables; rates and proportions were calculated for
categorical data. Normality of distribution for quantitative
variables was assessed by the Shapiro-Wilk test. Some variables
(Leptin, Leptin/sOb-R ratio, Adiponectin, Resistin, TNF-a, IL-18
and hs-CRP) did not show normal distribution, and the natural
logarithmic transformed (Ln) values of each adipocytokine for
statistical analysis were used. Differences between the two groups
were detected by the unpaired Student’s t test for continuous
variables (after testing for equality of variance: Levene test) and by
the x2-test and Fisher’s exact test (when appropriate) for
categorical variables. Correlations among anthropometric indices
and adipocytokines were analysed using the Pearson’s test.
In order to identify patients with Hypothetical ATD (HATD),
we performed a two-step cluster analysis using log-likelihood
distance measures. This technique can detect latent relationships
within a complex data set between patients with multiple distinct
characteristics. Cluster analysis was applied using an a priori
number of fixed clusters (cluster 1 and cluster 2) and the following
continuous variables were included in the analysis: Ln Leptin/
sOb-R ratio, Ln Adiponectin, Ln Resistin, Ln NEFA and Ln
TNF-a. The selection of the variables included in the analysis was
made on the basis of the Silhouette Coefficient obtained by
including various combinations of adipocytokines. The 5 variables
included produced a Silhouette Coefficient .0.5, indicative of a
good partitioning of data. The two clusters identified were
designated as ‘‘normal adipose tissue function’’ (cluster 1) and
HATD (cluster 2). For comparison between cluster 1 and cluster 2,
the group sizes gave 74.84% power to detect a moderate effect size
(Cohen’s d= 0.5) using T-test, with alpha at 0.05. Post-hoc power
analysis was performed using G*Power Version 3.1.6 software.
The receiver-operating characteristic (ROC) curve analysis was
conducted using the MedCalc software v. 9.3.8.0 for Windows
[which uses calculation of the area under the curve (C-statistic) and
95% confidence intervals by the technique of Hanley and
McNeil], to evaluate the diagnostic performance of the various
anthropometric indices (BMI, WC, HC, WHR, BAI, VAI) for
predicting HATD. The differences between C-statistics were
calculated by the method of Hanley and McNeil.
A p value of ,0.05 was considered statistically significant.
Results
The 91 patients studied consisted in 49 women and 42 men; the
clinical characteristics, the glycometabolic state and the adipocy-
tokine pattern are summarized in Table 1. Regarding the
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anthropometric indices, the women showed a higher BMI
(30.3564.94 vs. 28.3664.09 kg/m2, p = 0.039), HC (110.306
11.66 vs. 103.6667.40 cm, p= 0.001), BAI (37.0966.27 vs.
30.3164.17, p,0.001), VAI (2.6461.56 vs. 1.8760.94,
p = 0.005) and a lower WHR (0.9360.10 vs. 0.9860.04,
p = 0.012). Regarding the adipocytokine profile, only significantly
higher levels of leptin (13.74612.02 vs. 3.5964.79 ng/dl, p,
0.001) and significantly lower levels of sOb-R (19.8966.18 vs.
23.1066.40 ng/ml, p = 0.018) were found in women as compared
to men. No other gender difference was found.
Comparison of Various Anthropometric Indices with the
Adipocytokines, Lipid and Glycemic Parameters
BMI. BMI showed a significant positive correlation with Ln
Leptin, Ln Leptin/sOb-R ratio, HOMA IR, fasting C-peptide and
fasting Insulin; by contrast, a significant inverse correlation was
observed with sOb-R and Ghrelin (Table 2).
WC. WC showed a significant positive correlation with Ln
Leptin, Ln Leptin/sOb-R ratio, Ln Resistin, Ln hs-CRP, HOMA
IR, fasting C-peptide and fasting Insulin, fasting Glucose and
HbA1c; a significant inverse correlation was observed with sOb-R
and Ghrelin (Table 2).
HC. HC, excluding Ghrelin, showed similar significant
correlations to BMI (Table 2).
WHR. WHR significantly correlated with Ghrelin, Ln TNF-
a, IL-6, VEGF and fasting glucose.
BAI. BAI showed significant correlations only with Ln Leptin,
sOb-R, Ln Leptin/sOb-R ratio, HOMA IR and fasting Insulin.
VAI. VAI is the anthropometric index that showed the largest
number of correlations with adipocytokines. Significant positive
correlations were found with Ln Leptin, Ln Leptin/sOb-R ratio,
Visfatin, Ln Resistin, IL-6, Ln IL-18, VEGF, HGF, Ln hs-CRP,
Total Cholesterol, LDL Cholesterol, NEFA, HOMA IR, fasting
C-peptide and fasting Insulin. Significant inverse correlations were
observed with sOb-R, Ghrelin and Ln Adiponectin.
Two-Step Cluster Analysis
In order to identify a group of patients with the most altered
adipocytokine profile, classifiable as patients with HATD, a two-
step cluster analysis was performed (based on the selection of Ln
Leptin/sOb-R ratio, Ln Adiponectin, Ln Resistin, Ln NEFA and
Ln TNF-a. Two clusters were identified (Cluster 1 = 36 patients;
Cluster 2= 55 patients) of which cluster 2 showed the worst
adipocytokine profile (Figure 1). Regarding the specific parameters
of diabetes (duration of disease, HbA1c, HOMA IR, glycemic
profile), there were no significant differences between the two
clusters (Table 3). Significant differences were observed for lipids
and adipocytokines. Indeed, cluster 2 showed significantly higher
levels of triglycerides (1.5860.61 vs. 1.1460.38 mmol/l; p,
0.001), NEFA (0.5460.28 vs. 0.3660.20 mmol/l, p = 0.001) and
lower levels of HDL cholesterol (1.1460.22 vs. 1.4360.37 mmol/
l, p,0.001); no difference was found for total cholesterol and LDL
cholesterol. Furthermore, cluster 2 identified patients with higher
levels of Ln Leptin (1.7861.22 vs. 1.1561.18 ng/dl, p = 0.017),
Ln Leptin/sOb-R ratio (2 1.1661.46 vs.–1.9661.20, p = 0.007),
Ln Resistin (1.1760.91 vs. 0.8260.60 ng/ml, p= 0.031), Visfatin
(0.7460.61 vs. 0.4560.33 ng/ml, p = 0.014), Ln TNF-a
(0.3260.89 vs.–0.8160.84 pg/ml, p,0.001), Ln hs-CRP (2
1.2261.29 vs.–1.9761.32, p= 0.004), VEGF (138.13698.53 vs.
71.04680.51 pg/ml, p = 0.001), HGF (411.456193.95 vs.
299.676183.82 pg/ml, p = 0.007) and lower levels of sOb-R
(20.2066.98 vs. 23.1665.16 ng/ml, p = 0.022) and Ln Adipo-
nectin (1.1761.22 vs. 2.8360.81 mg/ml, p,0.001). No significant
differences were found for Adipsin, Ghrelin, PAI-1, IL-6 and IL-
18.
Figure 2. ROC Curves of the various anthropometric indices (BMI, WC, HC, WHR, BAI, VAI) for ‘‘hypothetical adipose tissue
dysfunction’’ (Cluster 2).
doi:10.1371/journal.pone.0091969.g002
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ROC Curve Analysis
ROC curve analysis was performed for BMI, WC, HC, WHR,
BAI and VAI to evaluate their diagnostic performance for
predicting an HATD (Table 4).
C-statistics were then compared to identify which parameter
was a better indicator for HATD. The C-statistics were 0.588
(95% CI 0.48–0.69) for BMI, 0.573 (95% CI 0.46–0.67) for WC,
0.507 (95% CI 0.40–0.61) for HC, and 0.574 (95% CI 0.46–0.67)
for WHR, 0.537 (95% CI 0.42–0.64) for BAI and 0.767 (95% CI
0.66–0.84) for VAI. VAI showed a significantly higher C-statistic
compared to BMI (difference: 0.178; 95% CI: 0.03–0.32; SE: 0.07;
p = 0.014), WC (difference: 0.194; 95% CI: 0.04–0.34; SE: 0.07;
p = 0.009), HC (difference: 0.260; 95% CI: 0.11–0.40; SE: 0.07;
p,0.001), WHR (difference: 0.193; 95% CI: 0.04–0.33; SE: 0.07;
p = 0.009) and BAI (difference: 0.230; 95% CI: 0.08–0.37; SE:
0.07; p = 0.001) (figure 2). No difference in C-statistic was found
among the other anthropometric indices.
Conclusions
We demonstrate in this study that the VAI is a good indicator of
an altered adipokine profile and its associated cardiometabolic
risk.
The emerging paradigm of ATD supports the view that adipose
tissue dysregulation (altered fat distribution and function) might
play a crucial role in the pathogenesis of insulin resistance and
atherosclerosis. From this viewpoint, atherosclerotic cardiovascu-
lar disease and DM2 seem to arise from a ‘‘common soil’’,
characterized by altered adipocytokine production, increase in the
lipolytic activity of adipose tissue and low-grade inflammation [24–
26]. In addition, recently the hypothesis that subcutaneous AT has
a limited capacity to increase its mass safely has been gaining
increasing recognition [27,28]. This capacity is individually
determined by a wide range of environmental and genetic factors.
The absence of adaptive hyperplasia of the subcutaneous adipose
tissue could be associated with visceral obesity and excess ectopic
fat.
We studied the ability of various common anthropometric
indices to correlate with a wide panel of adipocytokines. Though
the literature data show a continued involvement of new
adipocytokines, we chose to study some of those that have more
scientific evidence about their ability to express a condition of
ATD [29,30].
In our DM2 patients there were no gender differences except as
regards the leptinemic system: leptin levels are higher in women
than in men and the level of its soluble receptor is inversely
proportional; this known datum could be an expression of a state
of relative leptin resistance in women with diabetes [31]. Also
supporting this hypothesis is the observation of higher levels of
NEFA in women, which may reflect the reduction of anti-lipotoxic
activity carried out by leptin [32].
Among all the anthropometric indexes studied the VAI is the
one that showed the greatest number of correlations with the
adipocytokines and the lipids (including NEFA). The VAI was able
to express both the altered endocrine function of adipose tissue
and the state of relative leptin resistance and low-grade
inflammation, which are all alterations present in a state of
ATD. Particularly strong is the correlation with visfatin (adipocy-
tokine prevalently secreted by visceral adipose tissue, which
according to some authors may have adipogenic effects and is a
good candidate to explain the accumulation of visceral adipose
tissue associated with insulin resistance) [33,34], resistin (a
potential mediator of obesity related insulin resistance in rodents,
but still today a subject of controversy in human obesity and
human epidemiologic studies) [35] and hs-CRP (systemic markers
of inflammation, which have been found to independently predict
future coronary heart disease in type 2 diabetes) [36]. Further-
more, among all the indices it was the only one that showed an
inverse correlation with adiponectin. This datum, also confirmed
in other studies [9,17,21], is of major significance, given that the
adiponectin reduction is a key player in the development of
cardiovascular complication in DM2, because it is the only known
protective adipocytokine with insulin-sensitizing, anti-inflammato-
ry and anti-atherogenic properties [29,37,38]. Lastly, it is also
worth noting the significant association of VAI with VEGF and
HGF, an expression of the fact that activated adipocytes produce
multiple angiogenic factors including leptin, HGF, VEGF, which
stimulate neovascularization during fat mass expansion [39].
However, the primary difficulty of our study was to test the
diagnostic ability of the various anthropometric indices towards a
clinical entity such as ATD, which to date has still not been
univocally framed. For these reasons we used the two-step cluster
analysis, to identify the patients with the worst adipocytokines
profile, and use cautiously the diction ‘‘hypothetical adipose tissue
dysfunction’’. A limitation of our study, however, consists in the
fact that since all patients have a DM2, though not in a phase of
glycemic decompensation, it is assumed that all have a certain
degree of ATD. This datum is also apparent from the fact that,
despite the differences in the adipocitokine levels between the two
clusters, there were no significant differences regarding the
glycemic parameters (HbA1c, HOMA IR, glycemic profile), as if
the ATD only concerned the nonglycemic aspects of insulin-
resistance. Probably, the overlap between the two groups for
glycemic control and insulin sensitivity, despite the different
adipocytokine profile, it could also be due to extrahepatic actions
of metformin, able to activate AMP-activated protein kinase and
reduce acetyl-CoA carboxylase protein levels in human adipose
tissue in vivo [40]. The utility of the VAI in patients with diabetes
does not lie in the ability to assess the cardiovascular risk linked to
glucose toxicity (for these aspects the most important parameter is
always HbA1c), but it might mirror the residual cardiovascular risk
despite the normalization of glycemic, lipid and hemodynamic
parameters [41]. Finally, in our study we also identified a precise
cut-off of the VAI able to identify a HATD. This cut-off of 2 seems
to be comparable to the cut-off point identified, in the same age
range, in a previous study (in which in the general population an
ATD dysfunction is hypothesized in subjects with metabolic
syndrome) [10].
In conclusion, although still lacking prospective studies that can
attribute to the VAI a prognostic role on cardiovascular risk, given
the simplicity of WC and BMI measurement and Triglycerides
and HDL Cholesterol assessment, we suggest that the VAI would
be an easy tool for the evaluation of the cardiometabolic risk in
type 2 diabetes or in other populations, mainly in the absence of
an overt metabolic syndrome.
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